Stock Analysis·← Pickers

DGX

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated (DGX) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 44.3, with 3/3 trend checks passing.

Price
$201.77
2026-07-16
Trend score
3/3
Uptrend
RSI (14)
44.3
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

DGX with MA50 and MA200

216.0203.9191.7179.6167.407/3110/2401/2204/1707/15
DGX2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$199.02+1.38% vs price
MA200
$191.69+5.26% vs price
RSI (14)
44.3Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
$168.46–$177.3912.1% below price · 4 touches
Support Quality
4 touches1.1× zone volume
Chart Summary
Trend summary for DGX

Quest Diagnostics Incorporated (DGX) is still trading in a constructive trend overall. The latest available price is $201.77, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 1.4% and above the 200-day moving average by 5.3%.

Momentum and stretch context

DGX currently has an RSI reading of 44.3, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing DGX next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James E. Davis
Employees
57,000
Market cap
$22.34B
Beta
0.57
52-week range
$165.19 – $219.20
Dividend
Yes · $3.32
Exchange
NYSE
Country
US
IPO date
17 Dec 1996
ISIN
US74834L1008
CUSIP
74834L100
Company profile data from Financial Modeling Prep. DGX listed on NYSE.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about DGX

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.